Related Experiment Videos
2'-2'-difluorodeoxycytidine: in vitro effects on cell-mediated immune response
E Alvino1, M P Fuggetta, M Tricarico
1Institute of Experimental Medicine CNR, Rome, Italy.
Anticancer Research
|December 22, 1998
Summary
Gemcitabine (dFdC) shows immunotoxicity by inhibiting the generation of interleukin 2-activated killer (LAK) and cytotoxic T-lymphocyte (CTL) cells. Natural killer (NK) cell activity is only slightly affected by this deoxycytidine analogue.
Area of Science:
- Immunology
- Pharmacology
- Cancer Research
Background:
- Limited data exist on the immunotoxicity of gemcitabine (2 -2 -Difluorodeoxycytidine, dFdC), a novel deoxycytidine analogue.
- Gemcitabine is a widely used chemotherapy agent, necessitating an understanding of its impact on the immune system.
Purpose of the Study:
- To investigate the immunotoxic effects of gemcitabine (dFdC) on key cellular components of cell-mediated immunity.
- To evaluate the drug's impact on natural killer (NK), interleukin 2-activated killer (LAK), and antigen-dependent cytotoxic effector cells (CTL) activities.
Main Methods:
- Gemcitabine (dFdC) treatment of NK, LAK, and CTL cells.
- Assessment of cytotoxic activity using a 4-hour 51Cr-release assay.
- Evaluation of drug effects on both immune cell generation and mature effector function.
Main Results:
- Gemcitabine (dFdC) markedly inhibited the generation of LAK and CTL cells.
- The drug demonstrated less inhibition on the function of mature LAK and CTL lymphocytes.
- Gemcitabine (dFdC) exhibited only slight inhibition of NK cell activity.
Conclusions:
- Gemcitabine (dFdC) can be considered immunotoxic, primarily affecting the generation of adaptive immune responses.
- The findings highlight a potential for gemcitabine to impair cell-mediated immunity, impacting both natural and antigen-dependent pathways.